Selected research
Industry Growth & Trends
Global AL Amyloidosis Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global AL Amyloidosis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for AL Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for AL Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for AL Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the AL Amyloidosis Therapeutics market include Janssen Pharmaceutical, Pfizer, GlaxoSmithKline Pharmaceuticals Ltd, Bristol-Myers Squibb, Spectrum Pharmaceuticals, Inc., Prothena, Oncopeptides AB, Eidos Therapeutics, Inc. and Corino Therapeutics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global AL Amyloidosis Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The AL Amyloidosis Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global AL Amyloidosis Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to AL Amyloidosis Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global AL Amyloidosis Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
AL Amyloidosis Therapeutics Market by Company
Janssen Pharmaceutical
Pfizer
GlaxoSmithKline Pharmaceuticals Ltd
Bristol-Myers Squibb
Spectrum Pharmaceuticals, Inc.
Prothena
Oncopeptides AB
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Alexion Pharmaceuticals
AL Amyloidosis Therapeutics Segment by Type
Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy
AL Amyloidosis Therapeutics Segment by Application
Clinics
Hospitals
Ambulatory Service Centres
Others
AL Amyloidosis Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AL Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AL Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AL Amyloidosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of AL Amyloidosis Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy
- Supportive Care
- Surgery
- Stem Cell Transplant
- Targeted Therapy
Applications
- Clinics
- Hospitals
- Ambulatory Service Centres
- Others
Companies covered
- Janssen Pharmaceutical
- Pfizer
- GlaxoSmithKline Pharmaceuticals Ltd
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals, Inc.
- Prothena
- Oncopeptides AB
- Eidos Therapeutics, Inc.
- Corino Therapeutics, Inc.
- Alexion Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global AL Amyloidosis Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global AL Amyloidosis Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global AL Amyloidosis Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global AL Amyloidosis Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions AL Amyloidosis Therapeutics Market Size (2021-2032)
- 1.5.1 North America AL Amyloidosis Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe AL Amyloidosis Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific AL Amyloidosis Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America AL Amyloidosis Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa AL Amyloidosis Therapeutics Market Size Growth Rate (2021-2032)
2 AL Amyloidosis Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Chemotherapy
- 2.1.2 Supportive Care
- 2.1.3 Surgery
- 2.1.4 Stem Cell Transplant
- 2.1.5 Targeted Therapy
- 2.2 Global AL Amyloidosis Therapeutics Market Size by Type
- 2.2.1 Global AL Amyloidosis Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global AL Amyloidosis Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global AL Amyloidosis Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global AL Amyloidosis Therapeutics Market Size by Regions
- 2.3.1 North America AL Amyloidosis Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe AL Amyloidosis Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific AL Amyloidosis Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America AL Amyloidosis Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa AL Amyloidosis Therapeutics Market Size Breakdown by Type (2021-2026)
3 AL Amyloidosis Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Clinics
- 3.1.2 Hospitals
- 3.1.3 Ambulatory Service Centres
- 3.1.4 Others
- 3.2 Global AL Amyloidosis Therapeutics Market Size by Application
- 3.2.1 Global AL Amyloidosis Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global AL Amyloidosis Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global AL Amyloidosis Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global AL Amyloidosis Therapeutics Market Size by Regions
- 3.3.1 North America AL Amyloidosis Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe AL Amyloidosis Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific AL Amyloidosis Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America AL Amyloidosis Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa AL Amyloidosis Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 AL Amyloidosis Therapeutics Industry Trends
- 4.2 AL Amyloidosis Therapeutics Industry Drivers
- 4.3 AL Amyloidosis Therapeutics Industry Opportunities and Challenges
- 4.4 AL Amyloidosis Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by AL Amyloidosis Therapeutics Revenue (2021-2026)
- 5.2 Global AL Amyloidosis Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global AL Amyloidosis Therapeutics Key Company Headquarters & Area Served
- 5.4 Global AL Amyloidosis Therapeutics Company, Product Type & Application
- 5.5 Global AL Amyloidosis Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global AL Amyloidosis Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 AL Amyloidosis Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 AL Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Janssen Pharmaceutical
- 6.1.1 Janssen Pharmaceutical Company Information
- 6.1.2 Janssen Pharmaceutical Business Overview
- 6.1.3 Janssen Pharmaceutical AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Janssen Pharmaceutical AL Amyloidosis Therapeutics Product Portfolio
- 6.1.5 Janssen Pharmaceutical Recent Developments
- 6.2 Pfizer
- 6.2.1 Pfizer Company Information
- 6.2.2 Pfizer Business Overview
- 6.2.3 Pfizer AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Pfizer AL Amyloidosis Therapeutics Product Portfolio
- 6.2.5 Pfizer Recent Developments
- 6.3 GlaxoSmithKline Pharmaceuticals Ltd
- 6.3.1 GlaxoSmithKline Pharmaceuticals Ltd Company Information
- 6.3.2 GlaxoSmithKline Pharmaceuticals Ltd Business Overview
- 6.3.3 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Product Portfolio
- 6.3.5 GlaxoSmithKline Pharmaceuticals Ltd Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb AL Amyloidosis Therapeutics Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Spectrum Pharmaceuticals, Inc.
- 6.5.1 Spectrum Pharmaceuticals, Inc. Company Information
- 6.5.2 Spectrum Pharmaceuticals, Inc. Business Overview
- 6.5.3 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 6.5.5 Spectrum Pharmaceuticals, Inc. Recent Developments
- 6.6 Prothena
- 6.6.1 Prothena Company Information
- 6.6.2 Prothena Business Overview
- 6.6.3 Prothena AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Prothena AL Amyloidosis Therapeutics Product Portfolio
- 6.6.5 Prothena Recent Developments
- 6.7 Oncopeptides AB
- 6.7.1 Oncopeptides AB Company Information
- 6.7.2 Oncopeptides AB Business Overview
- 6.7.3 Oncopeptides AB AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Oncopeptides AB AL Amyloidosis Therapeutics Product Portfolio
- 6.7.5 Oncopeptides AB Recent Developments
- 6.8 Eidos Therapeutics, Inc.
- 6.8.1 Eidos Therapeutics, Inc. Company Information
- 6.8.2 Eidos Therapeutics, Inc. Business Overview
- 6.8.3 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 6.8.5 Eidos Therapeutics, Inc. Recent Developments
- 6.9 Corino Therapeutics, Inc.
- 6.9.1 Corino Therapeutics, Inc. Company Information
- 6.9.2 Corino Therapeutics, Inc. Business Overview
- 6.9.3 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 6.9.5 Corino Therapeutics, Inc. Recent Developments
- 6.10 Alexion Pharmaceuticals
- 6.10.1 Alexion Pharmaceuticals Company Information
- 6.10.2 Alexion Pharmaceuticals Business Overview
- 6.10.3 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Product Portfolio
- 6.10.5 Alexion Pharmaceuticals Recent Developments
7 North America
- 7.1 North America AL Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 7.3 North America AL Amyloidosis Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe AL Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe AL Amyloidosis Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific AL Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific AL Amyloidosis Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America AL Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 10.3 South America AL Amyloidosis Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa AL Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa AL Amyloidosis Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst